Synoptics Introduces a New Division, Synoptics Health

26 Nov 2012

Synoptics, a world leader in the development and manufacture of innovative digital imaging systems for scientific applications, is delighted to introduce its new Division, Synoptics Health. This Division will focus on imaging techniques within the clinical environment.

Synoptics has been successfully developing and supplying imaging solutions to life science researchers across the globe since 1986. The new Synoptics Health Division is currently utilizing that expertise to provide a patented fluorescence protein detection system, which has been developed over four years in partnership with Queen Mary University of London (QMUL).

The rationale for commercializing this protein detection technology is that the recent draft of the NHS CFPP-01-01 consultation document which offers guidance on decontamination of reusable surgical instruments states that fluorescence provides increased sensitivity and quantification of residual proteins on surgical instruments. Synoptics Health is therefore exploiting its technology in this field to meet the needs of this consultation document.

Paul Ellwood, CEO of Synoptics Health stated: “Comments in the CFPP-01-01 consultation document indicate that fluorescence is the most sensitive method for detection of proteins on surgical instruments. During the development of our prototype system and reagents in collaboration with QMUL, we have achieved a 100-fold increase in the sensitivity of protein detection over current methods and we are launching our first commercial fluorescence protein detection product at Medica.”

Ellwood continued: “We feel the time is right for us to forge better links with decontamination professionals, which is why we have opened our new division. Being able to talk to us at Synoptics Health will allow them to see how easily they could implement our simple technology into their facility, secure in the knowledge they will be guided every step of the way. Using ultra sensitive testing will ensure their decontamination processes are working efficiently and more importantly, will provide increased confidence that the surgical instruments they are sending out really are clean and safe.”

ProReveal Test

Synoptics Health

Fluorescence Protein Detection Test ProReveal is a highly sensitive fluorescence-based patented protein detection test for checking the presence of residual protein on surgical instruments after going through a washer disinfector process. This cost-effective test (conforms to BS EN ISO 15883-1) delivers objective, visual and measurable results, removing any doubt as to whether a decontaminated instrument is safe for reuse. Key features • Rapid result in under 5 minutes with a PASS or FAIL indicator • Provides a quantitative measurement over the whole of the instrument • A visual indication as to the location of any residual protein • Can detect less than 50ng of residual protein • Follows the new CPFF-01-01 guidelines for fluorescence-based protein detection methods • 3D view of the instrument shows where protein is present and how much • Patented viewer and reagent spray

(0)

Links

Tags

Synoptics Introduces a New Division, Synoptics Health